Qumis | $2,200,000 | (Jan 22, 2025)
Zynap | $5,937,902 | (Jan 22, 2025)
Belfry | $12,000,000 | (Jan 22, 2025)
Certified by Founder
Lodge
Delphia Therapeutics
start up
United States
- Cambridge, Massachusetts
- 07/05/2024
- Series A
- $67,000,000
Delphia Therapeutics is a biotechnology company pioneering activation lethality, a new area of cancer therapeutics that target cancer's surprising vulnerability to oncogene overactivation. Delphia’s activation lethality platform offers the potential for first-in-class targeted cancer medicines that are effective on their own while also combating the emergence of drug resistance to classic targeted therapies.
- Industry Biotechnology Research
- Website https://www.delphiatx.com/
- LinkedIn https://www.linkedin.com/company/delphia-therapeutics/
Gravity | $13,000,000 | (Jan 22, 2025)
LeapXpert | $20,000,000 | (Jan 22, 2025)
BPR Hub | $2,600,000 | (Jan 22, 2025)
NovoLINC | Undisclosed Amount | (Jan 22, 2025)
IntusCare | $11,500,000 | (Jan 21, 2025)
ecoplanet | $16,571,680 | (Jan 21, 2025)
Sereact | $25,894,660 | (Jan 21, 2025)
Fundment | $55,157,175 | (Jan 21, 2025)
Men In Blazers Media Network | $150,000,000 | (Jan 21, 2025)